RICHMOND, Va., Feb. 18, 2016 -- WestRock today introduced PerfPak® Advantage, a medication package providing a compliance solution that improves adherence. The product’s unique design provides flexibility with various dosing regimens and ample billboard space for patient education and instructions, which makes it ideal for a wide variety of clinical trial requirements. The integrated blister and wallet card design provides a conveniently sized, portable package for patients that incorporates the highest child resistance rating (F=1) with a unique feature in the pill cavity that is also senior-friendly.
|
|||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/19e11819-4bd1-4ce3-81d1-ef796aee1939
“PerfPak Advantage was developed based on insights from medication adherence experts, customers and consumers,” said Keshav Sharma, director of sales and product development for WestRock Healthcare. “Our existing supply chain and dedicated clinical manufacturing capabilities in the U.S. and Europe ensure security of supply and reduce risk for our customers while offering them an adherence-enhancing solution that is good for patients.”
PerfPak Advantage includes a visible calendar that remains with the wallet card and allows patients to easily track their medications. The calendared blister enables better pill protection as well as a daily opportunity for patient education, dosage information, and side effect profiles. The wallet card is made of an environmentally friendly, paperboard-based packaging solution that increases the use of recyclable materials and reduces waste. The wallet cards use WestRock’s proprietary Easy Seal Plus coating that works with a variety of blister materials.
The development of PerfPak Advantage is part of WestRock’s long-standing commitment to further awareness and solutions for poor medication adherence, and rounds out WestRock’s suite of proven adherence-enhancing clinical solutions. Research by Gapgemini shows that half of all patients in the U.S. and Europe do not take their medicines as prescribed. Poor medication adherence can lead to worsening of disease, serious and avoidable health risks, increased hospitalizations and even death. The combined annual cost of non-adherence in the U.S. and Europe is estimated by ExpressScripts and others to be nearly $450 billion.
About WestRock
WestRock Company (NYSE:WRK) aspires to be the premier partner and unrivaled provider of paper and packaging solutions in consumer and corrugated markets. WestRock’s 41,000 team members support customers around the world from more than 250 operating and business locations spanning North America, South America, Europe and Asia. Learn more at westrock.com.
Business Inquiries:
1-800-864-2685
[email protected]
Investor Contacts
John Stakel
Senior Vice President, Treasurer
678-291-7901
[email protected]
Jason Thompson
Director, Investor Relations
804-444-2556
[email protected]
Media Contact
Tucker McNeil
Director, Corporate Communications
804-444-6397
[email protected]


Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
Google Secures Pentagon AI Deal for Classified Projects
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 



